Show simple item record

dc.contributor.authorDiao, X.
dc.contributor.authorCarlier, J.
dc.contributor.authorZhu, M.
dc.date.accessioned2019-10-08T19:43:52Z
dc.date.available2019-10-08T19:43:52Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85032978389&doi=10.1373%2fclinchem.2017.277152&partnerID=40&md5=eb7b35660f8aeb8e06de5123d06380c3
dc.identifier.urihttp://hdl.handle.net/10713/11120
dc.description.abstractBACKGROUND: In 2014, 2 novel synthetic cannabinoids, MN-18 and its 5-fluoro analog, 5F-MN-18, were first identified in an ongoing survey of novel psychoactive substances in Japan. In vitro pharmacological assays revealed that MN-18 and 5F-MN-18 displayed high binding affinities to human CB1 and CB2 receptors, with Ki being 1.65- 3.86 nmol/L. MN-18 and 5F-MN-18 were scheduled in Japan and some other countries in 2014. Despite increasing prevalence, no human metabolism data are currently available, making it challenging for forensic laboratories to confirm intake of MN-18 or 5F-MN-18. METHODS: We incubated 10 ?mol/L of MN-18 and 5F-MN-18 in human hepatocytes for 3 h and analyzed the samples on a TripleTOF 5600+ high-resolution mass spectrometer to identify appropriate marker metabolites. Data were acquired via full scan and informationdependent acquisition-triggered product ion scans with mass defect filter. RESULTS: In total, 13 MN-18 metabolites were detected, with the top 3 abundant metabolites being 1-pentyl-1Hindazole- 3-carboxylic acid, pentyl-carbonylated MN-18, and naphthalene-hydroxylated MN-18. For 5F-MN-18, 20 metabolites were observed, with the top 3 abundant metabolites being 5'-OH-MN-18, MN-18 pentanoic acid, and 1-(5-fluoropentyl)-1H-indazole-3-carboxylic acid. CONCLUSIONS: We have characterized MN-18 and 5FMN- 18 metabolism with human hepatocytes and highresolution mass spectrometry, and we recommend characteristic major metabolites for clinical and forensic laboratories to identify MN-18 and 5F-MN-18 intake and link observed adverse events to these novel synthetic cannabinoids.en_US
dc.description.sponsorshipen_US
dc.description.urihttps://doi.org/10.1373/clinchem.2017.277152en_US
dc.language.isoen_USen_US
dc.publisherAmerican Association for Clinical Chemistry Inc.en_US
dc.relation.ispartofClinical Chemistry
dc.subject.mesh1-Naphthylamine--analogs & derivativesen_US
dc.subject.meshCannabinoids--metabolismen_US
dc.subject.meshFluorine--chemistryen_US
dc.subject.meshHepatocytes--metabolismen_US
dc.subject.meshIndazoles--metabolismen_US
dc.titleHuman hepatocyte metabolism of novel synthetic cannabinoids MN-18 and its 5-fluoro analog 5F-MN-18en_US
dc.typeArticleen_US
dc.identifier.doi10.1373/clinchem.2017.277152
dc.identifier.pmid28821542


This item appears in the following Collection(s)

Show simple item record